Paris, France · StartupBioptimus is the self-proclaimed "Mistral of Biology," spun out in early 2024 by a team of alumni from Google DeepMind and Owkin, including CEO Jean-Philippe Vert. The company is building what it calls the first universal foundation model for biology. Where large language models were trained on text to learn human language, Bioptimus trains on biological data—DNA sequences, protein structures, cellular imagery, and clinical phenotypes—to infer the underlying rules of life. The ambition is not just better predictions but a unified biological reasoning layer that can simulate outcomes before expensive lab work happens.
By 2026, Bioptimus has moved from a research thesis to early commercial traction. After a $41M Series A in 2025, the company released its first commercial model that can predict how a specific molecule will interact with a human cell with unusually high accuracy. This enables in-silico screening that reduces wet-lab costs and improves hit rates for drug discovery. French pharma leaders such as Sanofi have begun using these models to prioritize compounds and compress early-stage discovery timelines. The product value is immediate: fewer failed experiments, faster candidate selection, and deeper mechanistic insight.
Bioptimus' roadmap focuses on "multi-scale biology," connecting the micro level (genomics and proteomics) to the macro level (patient outcomes and clinical data). Rather than being limited to protein folding, the models aim to bridge across data modalities so a genetic mutation can be linked to disease pathways, tissue behavior, and potential therapeutic interventions. This requires data breadth and regulatory trust, and Bioptimus is building a defensive moat through European data sovereignty. It leverages partnerships with European research hospitals and biobanks to access high-quality patient data that is difficult for US competitors to acquire under GDPR constraints. That compliance burden becomes a competitive advantage: safer access, better provenance, and stronger alignment with European health data governance.
The company remains deeply embedded in the Paris ecosystem. It was incubated inside Owkin before spinning out, maintains a presence around Station F, and benefits from the cross-pollination between French AI and biotech communities. Its investor base reflects that positioning: Sofinnova Partners, Bpifrance, Cathay Innovation, Xavier Niel, and Frst provide a blend of life-science expertise, sovereign capital, and deep-tech conviction. In 2026, Bioptimus is the clearest European bet that foundation models can unlock biology at scale—and a contender to become the default AI layer for drug discovery in Europe.
StartupGrowthBiotechAIHealthcare
Paris, France · Event OrganisatorOrganizer of ChangeNOW, a global summit focused on climate and impact innovation.
Event OrganisatorEventsClimate TechImpactSustainability
Berlin, Germany · Event OrganisatorOrganizer of the mRNA-Based Therapeutics Summit Europe series.
Event OrganisatorEventsBiotech
Paris, France · Event OrganisatorOrganises an annual event for insurance professionals to explore innovation, emerging technologies, and future trends in the insurance sector.
Event OrganisatorEventsInsuranceFinTech
Paris, France · StartupNeoplants is one of Europe's most consumer-friendly deep-tech startups, known for engineering "plants with a purpose." Its flagship product, Neo P1, is a golden pothos that has been genetically modified to actively metabolize volatile organic compounds (VOCs) such as formaldehyde and benzene—pollutants common in homes due to paint, furniture, and cleaning products. Rather than simply filtering air passively, the plant converts toxins into harmless sugars and amino acids, turning living organisms into functional indoor air purifiers.
The company began commercial sales in the United States, where GMO consumer regulations are more permissive, but 2026 marks a strategic pivot back to Europe. Neoplants is positioning itself to launch in the UK and select EU markets as the New Genomic Techniques (NGT) framework evolves. This regulatory shift is crucial: it could unlock a path for consumer biotech products to be sold in Europe at scale. Neoplants is actively engaging with regulators and policymakers to ensure its products meet safety and transparency standards, framing its technology as a climate and public-health benefit rather than a controversial GMO niche.
Neoplants is also a serious biotech company under the consumer-friendly brand. It operates a 12,000-square-foot R&D facility in Saint-Ouen, Paris, with capabilities closer to a pharma lab than a greenhouse. The 2026 R&D pipeline includes plants engineered to capture CO2 at orders-of-magnitude higher rates than typical trees, targeting corporate offices and commercial spaces where sustainability investments must be visible and measurable. That positions Neoplants for a dual-market strategy: consumer air purification today, B2B climate infrastructure tomorrow.
The company's ecosystem roots are strong. The founders, Lionel Mora and Patrick Torbey, met at Entrepreneur First in Paris, and Neoplants was an early resident at Station F. It also benefited from the Wilco healthcare and biotech accelerator. Its investors reflect the blend of deep-tech and consumer focus: True Ventures led the seed, Heartcore Capital and Collaborative Fund support the consumer angle, and angels such as Niklas Zennstrom and Xavier Niel provide strategic visibility. In 2026, Neoplants represents a "solarpunk" vision of European tech—advanced biology that is both functional and approachable, turning climate and health solutions into products people can live with.
StartupEarly StageBiotechConsumerClimate
Paris, France · Event OrganisatorOrganizer of Paris Blockchain Week and related startup competition programming for Web3 founders.
Event OrganisatorEventsWeb3BlockchainStartup Ecosystem
Loading comments...